Access Pharmaceuticals, maker of the MuGard oral mucositis treatment, has licensed the U.S. commercial rights to the product to AMAG Pharmaceuticals.
Under terms of the license agreement, AMAG will pay Access an upfront license fee of $3.3 million in exchange for exclusive commercial rights to MuGard in the U.S. AMAG will also purchase existing MuGard inventory from Access and will pay a tiered, double-digit royalty on net sales of MuGard to Access.
MuGard is an oral mucoadhesive designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. MuGard was launched in 2010 after receiving 510(k) clearance from the U.S. Food and Drug Administration.
